
Migraine Science
Headache Impact Test (HIT-6)
Posted on July 31 2023,
HIT-6 is a reliable and valid tool for discriminating headache impact across episodic and chronic migraine. It was designed to provide a global measure of adverse headache impact and was developed to use in screening and monitoring patients with headaches in both clinical practice and clinical research.
The four headache impact severity categories are little or no impact (49 or less), some impact (50–55), substantial impact (56–59), and severe impact (60–78).
Reference: Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6TM) across episodic and chronic migraine. Cephalalgia. 2011;31(3):357-367. doi:10.1177/0333102410379890.
Mon, Jul 20, 26
Migraine Treatment in Pregnancy and Breastfeeding
Migraine hits hardest during the reproductive years. Here is what the latest evidence says about which migraine medications are safe during pregnancy and breastfeeding, from triptans and NSAIDs to topiramate,...
Read MoreMon, Jul 13, 26
Rimegepant for Migraine Prevention: Real-World Evidence
New real-world data on rimegepant for migraine prevention: a 75 mg every-other-day gepant that also treats attacks. What the GEMA study found on response rates, dosing, and why earlier use...
Read MoreMon, Jul 13, 26
Placebo Response in Migraine Trials: What a 126-Study Analysis Found
A new Neurology meta-analysis of 126 acute migraine trials found that about 1 in 9 people reach 2-hour pain freedom on placebo alone, and that placebo response has been rising...
Read More




